Bellus Health, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit Biotech Investing
New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic Medical Device Investing
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19 Pharmaceutical Investing
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference Biotech Investing
Bristol Myers Squibb Receives European Commission Approval for Opdivo® in Combination with Cabometyx® as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma Biotech Investing
Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week Pharmaceutical Investing
Knight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor Conference Medical Device Investing
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer Biotech Investing
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 In Dry Eye Disease Associated With Meibomian Gland Dysfunction Medical Device Investing
ROSEN, SKILLED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action - BLU Biotech Investing
